Matt O'Brien
Stock Analyst at Piper Sandler
(2.10)
# 2,842
Out of 5,182 analysts
203
Total ratings
38.92%
Success rate
-6.92%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDT Medtronic | Maintains: Neutral | $105 → $91 | $87.91 | +3.51% | 10 | Apr 1, 2026 | |
| MMED Minimed Group | Initiates: Neutral | $16 | $13.80 | +15.94% | 1 | Mar 31, 2026 | |
| TELA TELA Bio | Maintains: Neutral | $1.25 → $1 | $0.60 | +67.90% | 8 | Mar 25, 2026 | |
| CNMD CONMED | Downgrades: Neutral | $55 → $39 | $36.93 | +5.61% | 15 | Mar 17, 2026 | |
| TNDM Tandem Diabetes Care | Upgrades: Overweight | $21 → $33 | $19.68 | +67.68% | 11 | Mar 17, 2026 | |
| PRCT PROCEPT BioRobotics | Maintains: Overweight | $50 → $28 | $23.27 | +20.33% | 6 | Feb 26, 2026 | |
| TMDX TransMedics Group | Maintains: Overweight | $140 → $160 | $109.20 | +46.52% | 14 | Feb 25, 2026 | |
| GMED Globus Medical | Reiterates: Overweight | $90 → $115 | $91.40 | +25.82% | 13 | Jan 8, 2026 | |
| KMTS Kestra Medical Technologies | Maintains: Overweight | $27 → $30 | $19.25 | +55.84% | 2 | Dec 12, 2025 | |
| SI Shoulder Innovations | Reiterates: Overweight | $18 | $14.82 | +21.46% | 2 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $75 | $65.68 | +14.19% | 13 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 → $25 | $11.07 | +125.84% | 4 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $26 → $32 | $9.63 | +232.29% | 2 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $155 → $82 | $86.67 | -5.39% | 3 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $15.94 | +38.02% | 3 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $9.72 | +85.19% | 1 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $12 | $7.48 | +60.43% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $180 → $165 | $119.45 | +38.13% | 10 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $3.5 | $3.50 | - | 7 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $255 → $140 | $120.27 | +16.40% | 5 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $310 | $199.42 | +55.45% | 8 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $250 → $330 | $329.52 | +0.15% | 13 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $28.05 | +78.25% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $16 | $25.21 | -36.53% | 7 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $115 | $61.28 | +87.66% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 → $12 | $4.54 | +164.32% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $380 → $420 | $339.14 | +23.84% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $13.69 | +82.62% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $0.61 | +394.23% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $4.00 | +12.50% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $93.03 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $4.23 | +254.61% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $71.46 | +52.18% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $17.30 | +362.43% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $4.37 | +174.60% | 1 | Jun 24, 2020 |
Medtronic
Apr 1, 2026
Maintains: Neutral
Price Target: $105 → $91
Current: $87.91
Upside: +3.51%
Minimed Group
Mar 31, 2026
Initiates: Neutral
Price Target: $16
Current: $13.80
Upside: +15.94%
TELA Bio
Mar 25, 2026
Maintains: Neutral
Price Target: $1.25 → $1
Current: $0.60
Upside: +67.90%
CONMED
Mar 17, 2026
Downgrades: Neutral
Price Target: $55 → $39
Current: $36.93
Upside: +5.61%
Tandem Diabetes Care
Mar 17, 2026
Upgrades: Overweight
Price Target: $21 → $33
Current: $19.68
Upside: +67.68%
PROCEPT BioRobotics
Feb 26, 2026
Maintains: Overweight
Price Target: $50 → $28
Current: $23.27
Upside: +20.33%
TransMedics Group
Feb 25, 2026
Maintains: Overweight
Price Target: $140 → $160
Current: $109.20
Upside: +46.52%
Globus Medical
Jan 8, 2026
Reiterates: Overweight
Price Target: $90 → $115
Current: $91.40
Upside: +25.82%
Kestra Medical Technologies
Dec 12, 2025
Maintains: Overweight
Price Target: $27 → $30
Current: $19.25
Upside: +55.84%
Shoulder Innovations
Nov 12, 2025
Reiterates: Overweight
Price Target: $18
Current: $14.82
Upside: +21.46%
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $75
Current: $65.68
Upside: +14.19%
Oct 31, 2025
Reiterates: Overweight
Price Target: $20 → $25
Current: $11.07
Upside: +125.84%
Oct 29, 2025
Reiterates: Overweight
Price Target: $26 → $32
Current: $9.63
Upside: +232.29%
Oct 24, 2025
Maintains: Overweight
Price Target: $155 → $82
Current: $86.67
Upside: -5.39%
Oct 10, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $15.94
Upside: +38.02%
Aug 18, 2025
Initiates: Overweight
Price Target: $18
Current: $9.72
Upside: +85.19%
May 9, 2025
Maintains: Overweight
Price Target: $20 → $12
Current: $7.48
Upside: +60.43%
Apr 15, 2025
Maintains: Overweight
Price Target: $180 → $165
Current: $119.45
Upside: +38.13%
Mar 6, 2025
Maintains: Neutral
Price Target: $5.5 → $3.5
Current: $3.50
Upside: -
Feb 28, 2025
Downgrades: Neutral
Price Target: $255 → $140
Current: $120.27
Upside: +16.40%
Feb 21, 2025
Maintains: Overweight
Price Target: $285 → $310
Current: $199.42
Upside: +55.45%
Feb 19, 2025
Reiterates: Overweight
Price Target: $250 → $330
Current: $329.52
Upside: +0.15%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $50
Current: $28.05
Upside: +78.25%
Feb 12, 2025
Maintains: Neutral
Price Target: $40 → $16
Current: $25.21
Upside: -36.53%
Feb 3, 2025
Maintains: Overweight
Price Target: $95 → $115
Current: $61.28
Upside: +87.66%
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $4.54
Upside: +164.32%
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $339.14
Upside: +23.84%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $13.69
Upside: +82.62%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $0.61
Upside: +394.23%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $4.00
Upside: +12.50%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $93.03
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $4.23
Upside: +254.61%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $71.46
Upside: +52.18%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $17.30
Upside: +362.43%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $4.37
Upside: +174.60%